Group 1 - The company, 康臣药业 (01681), announced a mid-term dividend of HKD 0.33 per share for the six months ending June 30, 2025, to be distributed on September 19, 2025 [1]

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事局成員包括執行董事安猛先生、朱荃教授及楊玉川先生；非執行董事張麗華博士；以及獨立非執行董事馮仲實 先生、李義凱教授、李灼光先生及段威武先生。 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 康臣葯業集團有限公司 | | 股份代號 | 01681 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月19日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Kangchen Pharmaceutical, which rose over 7% and reached a new high of 14.59 HKD since its listing [1] - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The net profit attributable to equity shareholders was 498 million RMB, reflecting a year-on-year growth of 24.6% [1] Group 2 - Basic earnings per share were reported at 0.59 RMB, with an interim dividend proposed at 0.33 HKD per share, up from 0.30 HKD in the same period last year [1] - The sales of nephrology product series grew approximately 28.0% compared to the same period last year, with the flagship product, Uremic Clear Granules, maintaining its market leadership [1] - The sales of the women's and children's product series increased by about 17.5% year-on-year, becoming the second largest revenue contributor for the company [1]

消息面上，康臣药业今日午间公布截至6月30日止六个月业绩称，期内收入为15.69亿元(人民币，下 同)，同比增约23.7%；公司权益股东应占溢利为4.98亿元，同比增约24.6%，每股基本及摊薄盈利分别 约为0.59元及0.58元。拟派中期股息每股0.33港元。 上半年集团的毛利为12.09亿元，同比增约27.6%，毛利增长主要由于销售增长。整体销售收入的增长主 要由于集团持续致力开拓产品市场以及发展全国各地的销售网络。此外，上半年集团的平均毛利率约为 77.1%，与2024年同期的74.7%相比，增长2.4个百分点，主要由于中药材原材料采购价格下降。(格隆 汇) 康臣药业(1681.HK)午后直线拉升，一度涨9.87%至14.81港元，股价创历史新高，市值超126亿港元。该 股年内已累涨超88%，较今年1月9日盘中创下的年内低点7.05港元已累涨110%。 ...

Core Viewpoint - Kangchen Pharmaceutical reported a significant increase in revenue and profit for the six months ending June 30, 2025, indicating strong business performance and growth potential in the pharmaceutical sector [1] Financial Performance - The company's revenue reached RMB 1.569 billion, representing a year-on-year growth of approximately 23.7% [1] - The profit attributable to equity shareholders was RMB 498 million, showing a year-on-year increase of about 24.6% [1] - Basic and diluted earnings per share were RMB 0.59 and RMB 0.58, respectively [1] - The company proposed an interim dividend of HKD 0.33 per share [1] Gross Margin and Profitability - The group's gross profit increased by approximately 27.6%, with the gross margin rising to 77.1% [1] - The improvement in gross margin was primarily due to sales growth and a decrease in the procurement prices of traditional Chinese medicine raw materials [1] Product Performance - Sales of nephrology product series grew by 28.0%, with Uremic Clear maintaining its leading position [1] - Sales of maternal and pediatric product series increased by 17.5%, becoming the second-largest source of revenue [1] - Sales of medical imaging contrast agents rose by 22.0% [1] - Other product series also recorded varying degrees of growth [1]

上半年，集团的毛利约为12.09元，同比增长27.6%。毛利增长主要是由于销售增长所致。平均毛利率约 为77.1%，同比增长2.4个百分点，主要是由于中药材原材料采购价格下降所致。 【财华社讯】康臣药业(01681.HK)公布，截至2025年6月30日止六个月，集团收入15.69亿元(人民币,下 同)，同比增加23.7%；权益股东应占溢利4.98亿元，同比增加24.6%；每股基本盈利0.59元。拟派中期息 0.33元。 截至发稿，康臣药业涨7.34%，报14.47港元。 本文源自：财华网 ...

Core Viewpoint - Kangchen Pharmaceutical (01681) experienced a significant stock price increase of over 7%, reaching a new high of 14.59 HKD since its listing, following the release of its interim financial results [1] Financial Performance - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The profit attributable to equity shareholders was 498 million RMB, reflecting a year-on-year growth of 24.6% [1] - Basic earnings per share were reported at 0.59 RMB, with an interim dividend proposed at 0.33 HKD per share, up from 0.30 HKD in the same period last year [1] Product Performance - Sales from the nephrology product line grew approximately 28.0% compared to the same period last year, with Uremic Clear Granules (尿毒清) remaining the company's flagship product and maintaining its market leadership [1] - The pediatric and women's health product line saw a sales increase of about 17.5% year-on-year, becoming the second largest revenue contributor for the company [1]

Group 1 - The core viewpoint of the article is that 康臣药业 reported significant revenue and profit growth for the six months ending June 30, 2025, indicating strong financial performance [1] Group 2 - The company's revenue for the period reached RMB 1.569 billion, representing a year-on-year increase of approximately 23.7% [1] - The profit attributable to equity shareholders was RMB 498 million, reflecting a year-on-year increase of about 24.6% [1]

Group 1: Financial Performance - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The profit attributable to equity shareholders was 498 million RMB, an increase of 24.6% compared to the previous year [1] - The basic earnings per share were 0.59 RMB, and an interim dividend of 0.33 RMB per share was proposed [1] Group 2: Product Performance - Sales of nephrology products grew approximately 28.0% year-on-year, with Uremic Clear Granules remaining the flagship product [1] - Sales of pediatric and women's products increased by about 17.5%, becoming the second-largest revenue contributor [1] - Sales of medical imaging contrast agents rose by approximately 22.0%, while skin products increased by 19.7% [1] - Other product categories, including liver and gallbladder series and other drugs, also saw growth rates of 4.6% and 5.4% respectively [1] Group 3: Gross Profit and Margin - The gross profit for the first half of 2025 was 1.209 billion RMB, up approximately 27.6% from 948 million RMB in the same period of 2024 [2] - The average gross margin was about 77.1%, an increase of 2.4 percentage points from 74.7% in the previous year, primarily due to a decrease in the procurement prices of Chinese medicinal materials [2]

Core Insights - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The profit attributable to equity shareholders was 498 million RMB, up 24.6% compared to the previous year [1] - The company proposed an interim dividend of 0.33 RMB per share [1] Revenue Breakdown by Product Series - The nephrology product series saw a sales increase of approximately 28.0%, with the flagship product, Uremic Granules, maintaining its market leadership [1] - The women's and children's product series experienced a sales growth of about 17.5%, becoming the second-largest revenue contributor [1] - Sales of medical imaging contrast agents grew by approximately 22.0% [1] - The bone injury product series recorded a sales increase of 2.1% [1] - The dermatology product series saw a sales growth of 19.7% [1] - The liver and gallbladder product series experienced a sales increase of 4.6% [1] - Other pharmaceuticals recorded a sales growth of 5.4% [1] - Overall sales revenue growth was attributed to the company's ongoing efforts to expand product markets and develop sales networks across the country [1] Gross Profit and Margin - The company's gross profit for the first half of 2025 was 1.209 billion RMB, an increase of approximately 27.6% compared to 948 million RMB in the same period of 2024 [2] - The average gross margin for the first half of 2025 was approximately 77.1%, up 2.4 percentage points from 74.7% in the previous year, primarily due to a decrease in the procurement prices of traditional Chinese medicine raw materials [2]